Teva Issues Voluntary Nationwide Recall of One Lot of Anagrelide Capsules, USP 0.5 mg Due to Dissolution Test Failure | FDA
Teva Recalls One Lot of Anagrelide Capsules, USP 0.5 mg Due to Dissolution Test Failure | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology
Teva Pharma Recalls One Lot Of Anagrelide Capsules
血小板增多症患者注意!因溶出度测试失败,这批阿那格雷被召回_Teva_批次_降低
FDA announces recall of platelet-reducing medication due to risk of clotting or other adverse cardiovascular outcomes
These highlights do not include all the information needed to use ANAGRELIDE CAPSULES safely and effectively. See full prescribing information for ANAGRELIDE CAPSULES. ANAGRELIDE capsules, for oral useInitial U.S. Approval: 1997
Anagrelide Teva 0.5mg cps.dur.100
Torrent Pharmaceuticals Recall Anagrelide Capsules over drug's Dissolution test Failure • Drugwatcher.org
Teva 00172524060 - McKesson Medical-Surgical
ANAGRELIDE HCL 0.5MG - RX Products
Dissolution Test Failure Prompts Recall of Anagrelide Capsules - MPR
These highlights do not include all the information needed to use ANAGRELIDE CAPSULES safely and effectively. See full prescribing information for ANAGRELIDE CAPSULES. ANAGRELIDE capsules, for oral useInitial U.S. Approval: 1997